** Drug and Medical device maker Johnson & Johnson JNJ.N beat Q1 estimates on strong sales of its cancer treatments, including multiple myeloma medicine Darzalex
** Median PT of 26 brokerages covering the stock is $169.50 - LSEG data
LOOKS SOMEWHAT IMMUNE DESPITE TARIFFS
** J.P.Morgan ("neutral," PT: $185) expects co to maintain steady growth, despite concerns about litigation and tariffs impacting sales in China
** RBC ("outperform," PT: $181) believes co is well-positioned for growth in MedTech due to its strong portfolio and innovation, particularly in heart failure treatments, electrophysiology, and surgical robotics
** TD Cowen ("buy," PT: $185) believes co can manage $400 mln tariff costs and still meet its 2025 earnings goals, which mainly affects its MedTech products shipped from the U.S. to China
** Morgan Stanley ("equal-weight," PT: $169) see JNJ's strategic investments as a positive move despite tariff impact
(Reporting by Rashika Singh in Bengaluru)
((rashika.singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.